Clinical Trial Update: Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN [NA]

View source ↗

Summary

A clinical trial is evaluating PET imaging with zirconium-labelled girentuximab in patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma
• Neuroendocrine Tumor

Drugs mentioned

• Zirconium-labelled girentuximab (girentuximab)

Snippet

Sponsor: Nantes University Hospital | Conditions: Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc) | NA | Status: RECRUITING